Codexis Inc
Slēgts
SektorsVeselības aprūpe
2.56 4.07
Pārskats
Akcijas cenas izmaiņa
24h
Min
2.5300000000000002
Max
2.63
Ienākumi | -18M -8.7M |
|---|---|
Pārdošana | -24M 15M |
EPS | -0.1 |
Peļņas marža | -57.083 |
Darbinieki | 146 |
EBITDA | -23M -6.4M |
Rekomendācijas | Pirkt (spēcīgs) |
|---|---|
Prognoze 12 mēnešiem | +168.48% upside |
Nākamie ieņēmumi | 2026. g. 12. aug. |
|---|
Tirgus kapitalizācija | -1.8M 226M |
|---|---|
Iepriekšējā atvēršanas cena | -1.51 |
Iepriekšējā slēgšanas cena | 2.56 |
Ziņu noskaņojums
By Acuity
50%
50%
129 / 342 Rangs Healthcare
Codexis Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Codexis Inc
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
